VenatoRx Pharmaceuticals Revenue and Competitors

Claim your profile



Total Funding



Estimated Revenue & Valuation

  • VenatoRx Pharmaceuticals's estimated annual revenue is currently $15.9M per year.(i)
  • VenatoRx Pharmaceuticals received $42.0M in venture funding in July 2017.
  • VenatoRx Pharmaceuticals's estimated revenue per employee is $201,000
  • VenatoRx Pharmaceuticals's total funding is $107M.

Employee Data

  • VenatoRx Pharmaceuticals has 79 Employees.(i)
  • VenatoRx Pharmaceuticals grew their employee count by -12% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

Led by a world-class team of pharmaceutical veterans, VenatoRx is a private pharmaceutical company that is developing a new wave of anti-infective products to address increasing medical needs. VenatoRx's lead product, VNRX-5133, is an injectable broad-spectrum beta-lactamase inhibitor (BLI) that directly inhibits all four Ambler classes of beta-lactamases. Early clinical studies of cefepime/VNRX-5133 have been completed and VenatoRx plans to start Phase 3 pivotal trials in the second half of 2018. In addition, VenatoRx has a broad pipeline of preclinical programs, including a broad-spectrum orally bioavailable BLI, a novel class of Penicillin-Binding Protein (PBP) inhibitors that are impervious to beta-lactamase-driven resistance, and novel antiviral agents.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





VenatoRx Pharmaceuticals News

2022-03-30 - Venatorx Pharmaceuticals Raises Series C Financing

Venatorx Pharmaceuticals, Inc., a Malvern, PA-based private, clinical-stage pharmaceutical company focused on improving health outcomes for...

2022-03-30 - AMR Action Fund Announces First Investments in Adaptive ...

"Adaptive Phage Therapeutics and Venatorx Pharmaceuticals are poised to change the treatment landscape for drug-resistant infections," said AMR...

2022-03-30 - Venatorx Pharmaceuticals Raises Series C Financing Led by ...

Venatorx is a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant...

2019-09-07 - VenatoRx Pharmaceuticals Names Joseph C. Larsen, Ph.D. Vice President, Strategic Portfolio Development

MALVERN, Pa.--(BUSINESS WIRE)--. VenatoRx Pharmaceuticals today announced that Joseph C. Larsen, Ph.D. has joined the Company as ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

VenatoRx Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2017-07-26$42.0MBVersant VenturesArticle